Poloxamer Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer supplied as free-flowing prills or cast solid. The grade set includes Poloxamer 124, 188, 237, 338, and 407. The compendial limits for the 188 grade specify an average molecular weight range of 7680–9510 g/mol and an ethylene oxide content of 79.9–83.7%; the 407 grade is specified at 9840–14600 g/mol with 71.5–74.9% ethylene oxide. These two grades dominate veterinary formulation because they span the boundary between liquid-processable wetting agents and thermoreversible gel formers. Material released as veterinary grade is manufactured under ICH Q7 and is supported by residual ethylene oxide, residual 1,4-dioxane, butylated hydroxytoluene, peroxide value, water content, elemental impurity risk, and particle size data. The designation does not identify poloxamer as an active pharmaceutical ingredient; it identifies the material as a fully documented API-grade excipient suitable for incorporation into approved veterinary dosage forms.

Batch records typically include a gel permeation chromatography profile and a residual unsaturation value. Low-molecular-weight diol fractions and unsaturated polyoxypropylene monoalkyl ethers influence surface activity and oxidative susceptibility. For Poloxamer 407, gelation temperature is sensitive to these minor fractions even when average molecular weight remains within the compendial band; a shift in polydispersity above 1.2 can alter the fill temperature window and is therefore treated as a re-qualification event. Cast solid and prill forms are packed in low-density polyethylene liners inside fiber drums or multiwall paper sacks and should be stored below 25 °C and 40% RH to limit sintering. Fine particles below 100 µm generated during comminution of cast solids can bridge hoppers and reduce gravimetric feeder accuracy if their fraction exceeds 10% w/w.

Which Compendial and Supplier Limits Separate Veterinary Grade from Technical Poloxamer?

Technical poloxamer fluids sold for foam control or industrial wetting are not controlled for injectable-risk impurities. Veterinary grade release requires compendial identity, average molecular weight, ethylene oxide content, free ethylene oxide, dioxane, water content, heavy metals, and, for parenteral or intramammary products, bacterial endotoxins per Ph. Eur. 2.6.14. Industrial grades may contain higher low-molecular-weight glycol fractions that reduce cloud point and increase hygroscopicity. Technical block copolymer batches may also use broader monomer addition ratios and different neutralization histories, producing higher peroxide values and variable physical form. The veterinary specification typically fixes the supplier’s production train, packaging line, and antioxidant concentration so that batch-to-batch variation in tablet compression and wet granulation endpoints remains within qualified ranges. Elemental impurity risk is assessed under ICH Q3D; pharmacopoeial poloxamer monographs do not assign a universal endotoxin limit, so the parenteral developer must justify the limit from the finished-product dose and species-specific route. The difference from other products is most visible in the certificate of analysis: industrial fluids typically list viscosity, hydroxyl value, and water, while a veterinary grade certificate adds molecular weight distribution, ethylene oxide content, free ethylene oxide, dioxane, and optional bioburden.

The grades used in tablets, injections, capsules, powders, granules, premix, and oral solutions are selected from the following compendial ranges:

For release control across the dosage-form range, the following matrix is applied:

In direct compression of veterinary bolus and chewable tablets, the physical form of Poloxamer 188 controls initial blend uniformity. A prill product with d50 of 300–600 µm can segregate from finely milled active powders below 150 µm; screen sizing through a 500 µm sieve after pre-blending is therefore applied before compression. For wet granulation, the material is dry mixed at 2–5% w/w or dissolved in the granulating fluid; the dissolved fraction lowers surface tension and improves wetting of hydrophobic actives. The melting range of Poloxamer 188, approximately 52–57 °C, permits melt granulation in jacketed high-shear mixers and twin-screw melt extrusion with barrel temperatures below 55 °C, but restricts its use in high-energy tableting if sustained die wall friction raises die wall temperature above 45 °C. Hardness and disintegration times are batch-sensitive when the poloxamer fraction is below 2% w/w; compact tensile strength also shifts with granule moisture below 1.5% during dry storage, and the direction and magnitude must be established on the product-specific tablet press. Capsule filling requires control of the powder’s angle of repose; prill grades with low fine-particle content below 100 µm reduce dust and provide consistent volumetric filling. When poloxamer is used as a solubility enhancer in hard gelatin capsules, a hot-melt fill of Poloxamer 188 and active at 55–60 °C can be metered into size 0 or 1 capsules and solidified at 15–25 °C.

For water-dispersible granules and medicated premixes, Poloxamer 407 is incorporated by hot-melt coating onto carrier particles or by co-grinding with lactose or corncob carriers. Hot-melt coating is performed in a fluidized bed with inlet air temperature 40–50 °C; coating uniformity is assessed by suspensibility testing according to CIPAC MT 15.1. Granules should be dried to moisture below 1.5% to prevent agglomeration in foil sachets stored under tropical conditions. The powder surface becomes tacky above 60% RH, which reduces flow through rotary filling equipment and should be controlled with desiccant packs or barrier packaging.

When Poloxamer 407 Replaces Poloxamer 188 in Injectable or Intramammary Systems

When Poloxamer 407 replaces Poloxamer 188 in injectable or intramammary systems, the design boundary shifts from solubility to thermoreversible gelation. A 20% w/w aqueous solution of Poloxamer 407 typically forms a gel near 24–28 °C, below the core body temperature of cattle (38.5–39.5 °C) and swine (38–39 °C). The fluid is therefore filled as a cold liquid at 4–8 °C and gels after administration. Sodium chloride, phosphate buffers, and sodium citrate depress gelation temperature; ethanol and propylene glycol raise it. During aseptic filling, cold Poloxamer 407 solutions are passed through 0.22 µm sterilizing-grade filters below the gelation threshold, and the filling line must maintain solution temperature within 5–10 °C to avoid premature gelation in the transfer line. The aseptic filtration setup typically uses a two-stage 0.45 µm prefilter and 0.22 µm sterilizing-grade membrane. Pressure drop across the 0.22 µm membrane is recorded at 2–5 °C intervals because viscosity rises as the solution approaches the gel boundary. Filling needles and stainless-steel transfer lines are jacketed; dead-leg volumes are minimized because stagnant cold solution may warm above the gelation threshold and create soft gel plugs that are not easily detected by in-line pressure sensors. Poloxamer 188 does not form a firm gel at 20% w/w under 25 °C; it remains mobile and is preferred for injectable solutions requiring high cloud point and lower viscosity. Sterilization validation for Poloxamer 407 systems must evaluate filter pressure drop, cold-line residence time, and batch homogeneity because gel temperature is sensitive to monomer ratio and salt concentration.

For capsules and oral solutions, Poloxamer 188 differs from polysorbate 80 in degradation chemistry. Polysorbate 80 contains ester linkages that undergo pH- and temperature-dependent hydrolysis to free fatty acids; the resulting pH drift and turbidity are documented failure modes in aqueous veterinary formulations. Poloxamer 188 has no ester linkage, so hydrolysis to free fatty acid is not the primary degradation route; however, oxidative degradation can occur if headspace oxygen is not reduced and the solution is stressed. Compared with polyethylene glycol homopolymers, poloxamer has a central polypropylene oxide block that provides surface activity and micellar solubilization. Poloxamer 188 can be autoclaved at 121 °C for 15 min without phase separation, whereas polysorbate 80-based micelles may cloud or aggregate under the same terminal sterilization cycle. The cloud point of Poloxamer 188 is reported above 100 °C for 10% w/w aqueous solutions, while polysorbate 80 typically clouds at 65–90 °C depending on salt and pH. Compared with povidone binders, Poloxamer 188 can reduce disintegration time in some tablet formulations because it reduces interfacial tension rather than forming high-viscosity polymer films; the effect is formulation dependent and is evaluated with USP <701> and USP <711> type apparatus.